Targets › TNFRSF13C
6 programs from 6 companies in 22 trials: 11 Phase 3, 6 Phase 1, 5 Phase 2; Oncology, Hematology, Immunology; next expected readout Nov 2026.
B-cell receptor specific for TNFSF13B/TALL1/BAFF/BLyS. Promotes the survival of mature B-cells and the B-cell response. (UniProt, Q96RJ3)
Open in Phaseline: the race on TNFRSF13C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Novartis | Ianalumab (VAY736) Tumor necrosis factor receptor superfamily member 13C binding agent | TNFRSF13C | Phase 3 | Systemic Lupus Erythematosus; Sjogren Syndrome; Lupus Nephritis; Primary Immune Thrombocytopenia … | Mar 2027 |
| PeproMene Bio | BAFFR-CAR T cells BAFFR-targeting CAR T cell therapy | TNFRSF13C | Phase 1 | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma | Nov 2026 |
| Jiangsu Topcel-KH Pharmaceutical | BAFF-R CAR-T cells BAFF receptor-targeted chimeric antigen receptor T-cell therapy | TNFRSF13C | Phase 1 | B-cell Lymphoma | Jan 2027 |
| Tianjin Medical University General Hospital | BAFF-R CART CAR-T cell therapy targeting BAFF receptor | TNFRSF13C | Phase 1 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Dec 2027 |
| Paolo Caimi, MD | BAFF CAR-T (LMY-920) CAR-T cells expressing B-cell activating factor (BAFF) ligand targeting BAFF receptor | TNFRSF13C | Phase 1 | Relapsed CLL | Dec 2027 |
| Institute of Hematology & Blood Diseases Hospital, China | BAFF-R CAR-T BAFF-R-targeted chimeric antigen receptor T-cell therapy | TNFRSF13C | Phase 1 | DLBCL | Nov 2029 |
Systemic Lupus Erythematosus (3) Primary Immune Thrombocytopenia (ITP) (3) Lupus Nephritis (2) Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (1) Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (1) Sjogren Syndrome (1) Primary Immune Thrombocytopenia (1) Warm Autoimmune Hemolytic Anemia (wAIHA) (1) Sjögren´s Disease (1) Sjogrens Syndrome (1) Hidradenitis Suppurativa (1) Diffuse Cutaneous Systemic Sclerosis (1)
other (4), antibody (1), mixed (1)
PeproMene Bio (1) Novartis (1) Paolo Caimi, MD (1) Tianjin Medical University General Hospital (1) Jiangsu Topcel-KH Pharmaceutical (1) Institute of Hematology & Blood Diseases Hospital, China (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.